Vanderbilt-Ingram Cancer Center's Krista Kuhnert-Gainer, ACNP has performed more than 20,000 bone marrow biopsies since 1996.

Vanderbilt research found that a new drug company founded by entrepreneur Mark Cuban could save patients $1.29 billion a year based on 2020 Medicare Part D expenditures on just the nine most popular urological drugs.

Vanderbilt-Ingram Cancer Center is now participating in CancerLinQ, a technology initiative focused on improving patient care that tracks quality metrics in real time.

Jordan Berlin, MD, has been named director of Vanderbilt’s Division of Hematology and Oncology.

Vanderbilt surgeons recently treated a pancreatic cancer patient using IntraOp Mobetron IORT with electrons — the first surgery performed in Tennessee with this new technology utilizing intraoperative radiotherapy in the operating room.

Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.

A new approach for conducting gene-based analyses for cancer susceptibility created at Vanderbilt outperforms existing models.